Viwit
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biopharmaceutical company leveraging chiral borane chemistry and integrated R&D to develop innovative drugs and APIs across multiple therapeutic areas.
OphthalmologyCardiovascularInfectious DiseaseCentral Nervous SystemInflammation
Technology Platform
Core expertise in chiral borane chemistry for the synthesis of complex molecules, serving as a platform for developing APIs, intermediates, and novel therapeutics.
Opportunities
Growth opportunities include leveraging its established borane chemistry and CDMO platform for partnership revenue, expanding its commercial product portfolio in China and internationally, and successfully pivoting its R&D into high-value next-generation cell and gene therapies.
Risk Factors
Key risks include the high cost and failure rate associated with developing novel cell/gene therapies, potential reliance on generic drug revenue in a competitive market, and the execution challenge of balancing a service-based CDMO model with internal innovative R&D.
Competitive Landscape
Viwit competes with other integrated Chinese pharma companies and CDMOs (e.g., WuXi AppTec, Pharmaron in services; CSPC, Hengrui in generics/innovation). Its differentiation lies in its specialized borane chemistry expertise and its hybrid model of product development coupled with partnership services.